Roth Capital sets USD 475 target for Natera stock
Published on 10/27/2026 at 11:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKidney research and quarterly revenue
- Natera published 18 kidney research abstracts on October 26, 2026.
- Second-quarter revenue reached USD 752.75 million in the period ended June 30, 2026.
- Natera stock traded at EUR 362.15 at 11:39 a.m. CET at Lang & Schwarz on October 27, 2026.
Natera stock (ISIN US6323071042) was trading at EUR 362.15 at Lang & Schwarz on October 27, 2026 at 11:39 a.m. CET. The latest analyst catalyst came on October 23, 2026, when Roth Capital initiated coverage with a Buy rating and a USD 475 price target, as reported by MarketScreener.
Roth sees oncology potential
The analyst call puts Natera's oncology testing business at the center of the investment case. The USD 475 target was published after the company had reported USD 752.75 million in revenue for the second quarter ended June 30, 2026, according to MarketBeat. The same quarter produced a consolidated net loss of USD 66.97 million, while operating loss was USD 75.79 million.
For investors, the upcoming report will test whether the growth profile can narrow those losses. MarketBeat lists November 5, 2026, after the market close, as Natera's next quarterly reporting date and gives a consensus revenue estimate of USD 707.54 million for the third quarter.
What does the kidney research add?
Natera said on October 26, 2026, that 18 abstracts presented at the American Society of Nephrology Kidney Week 2026 examined genetic testing in chronic kidney disease. One analysis found a median 5.3-year delay between the first abnormal kidney indicator and a documented diagnosis, while another found that only one third of high-risk patients had documented nephrology care, according to Business Wire.
Three recent Natera events
On October 9, 2026, Natera said the FDA granted Breakthrough Device designation to its multi-cancer early detection assay after reviewing data from 12 cancer types, as reported by Yahoo Finance. On October 13, the company announced a Phase 2a colorectal cancer collaboration, and on October 26 it reported 18 kidney research abstracts.
Stock price and next report
The key near-term test is the November 5 reporting date, while the analyst target keeps attention on oncology growth and the path toward profitability.
The further course of trading is shown by the continuously updated real-time quote of Natera stock.
Natera stock key data
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 11:39 a.m. CET): EUR 362.15
- Market capitalization: USD 58.4 billion (as of October 26, 2026)
- 52-week range: USD 181.00-437.41 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Next earnings date: November 5, 2026
Market context: Market report Nasdaq Composite.
